A benefit-harm analysis of adding basal insulin vs. sulfonylurea to metformin to manage type 2 diabetes in people with multiple chronic conditions

The benefits and harms of diabetes treatments need to be carefully weighed in people with type 2 diabetes (DM) and multiple chronic conditions (MCCs). Our objective was to quantitatively assess the benefits and harms of the addition of basal insulin (insulin) vs. sulfonylurea (SU) to metformin in people with DM and MCCs.

Source: Journal of Clinical Epidemiology - May 2, 2019 Category: Epidemiology Authors: Wendy L. Bennett, H élène E. Aschmann, Milo A. Puhan, Craig W. Robbins, Elizabeth A. Bayliss, Renee Wilson, Richard A. Mularski, Wiley V. Chan, Bruce Leff, Orla Sheehan, Carol Glover, Katie Maslow, Karen Armacost, Suzanne Mintz, Cynthia M. Boyd Tags: Original Article Source Type: research